Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Study Summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Conditions

Solid Tumor Small Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer Small Cell Carcinomas of Non-lung Origin Non-small Cell Lung Cancer (NSCLC)Prostate Cancer Ovarian Cancer Renal Carcinoma (Clear and Non-clear Cell)Head and Neck Squamous Cell Carcinoma (HNSCC)Hepatic Cancer Gastric Cancer Triple-negative Breast Cancer (TNBC)

Interventions / Drugs

EXS74539

View on ClinicalTrials.gov ↗

Sponsor

RXRX

Recursion Pharmaceuticals

AI Drug Discovery

D38/100

Study Details

Enrollment40 participants

Primary Completion—

Lead SponsorExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:26:31.746388+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.